PD03: Benign Prostatic Hyperplasia: Basic Research & Pathophysiology
303A
Poster and Podium Sessions
BPH
Information
Continuing Medical Education
CME
Friday, May 3
PD03-03: Both Activator and Inhibitor of Transient Receptor Potential Mucolipin 1 (TRPML1) Inhibit Contractions Induced by Various Stimuli in Human Prostate Smooth Muscle.
Friday, May 3, 2024 7:20 AM to 7:30 AM
303A
PD03-04: Urinary Collagen Levels are Diagnostic for Men with Severe Lower Urinary Tract Symptoms (LUTS)
Friday, May 3, 2024 7:30 AM to 7:40 AM
303A
PD03-06: Mitochondrial complex I protein NDUFS3 is decreased in benign prostatic hyperplasia patients treated with celecoxib and/or finasteride.
Friday, May 3, 2024 7:50 AM to 8:00 AM
303A
PD03-08: The activated complement pathway in the fibrous process of benign prostatic hyperplasia
Friday, May 3, 2024 8:10 AM to 8:20 AM
303A
PD03-10: Concentration-dependent antagonism of α1-adrenergic smooth muscle contractions in human prostate tissues, and bidirectional effects on stromal cell growth by the dual β- and α1-adrenergic antagonist carvedilol
Friday, May 3, 2024 8:30 AM to 8:40 AM
303A
PD03-11: Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese
Friday, May 3, 2024 8:40 AM to 8:50 AM
303A